TIM-3 as a molecular switch for tumor escape from innate immunity by Fabrizio Mattei & Giovanna Schiavoni
GENERAL COMMENTARY
published: 09 January 2013
doi: 10.3389/fimmu.2012.00418
TIM-3 as a molecular switch for tumor escape from
innate immunity
Fabrizio Mattei* and Giovanna Schiavoni
Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy
*Correspondence: fabrizio.mattei@iss.it
Edited by:
Uday Kishore, Brunel University, UK
Reviewed by:
Uday Kishore, Brunel University, UK
A commentary on
Tumor-infiltrating DCs suppress nucleic
acid-mediated innate immune responses
through interaction between the receptor
TIM-3 and the alarmin HMGB1
by Chiba et al. (2012). Nat. Immunol. 13,
832–843.
Stimulation of immunity toward tumors
has always been one of the most objectives
of oncoimmunologists. The identification
and characterization of key molecules that
may potentially help immunity to con-
trast cancer progression is increasing over
time. Among these factors, TIM-3 is well-
recognized to have multiple key roles in
eliciting immunity toward pathogens. This
transmembrane protein was identified and
characterized for the first time 10 years
ago by Monney and coworkers, demon-
strating the expression of TIM-3 in dif-
ferentiated Th-1 lymphocytes (Monney
et al., 2002). In vivo, suppression of TIM-
3 was shown to enhance the pathologi-
cal severity of experimental autoimmune
encephalomyelitis (Monney et al., 2002;
Anderson and Anderson, 2006).
Here, Chiba and coworkers have evi-
denced the existence of a comprehen-
sive mechanistic pathway by which the
tumor microenvironment affects den-
dritic cell ability to regulate nucleic
acid-mediated innate immune pathways
through TIM-3. Indeed, immunosup-
pressive factors, such as VEGF-A and
IL-10 released by tumor cells, induce
expression of TIM-3 in dendritic cells
which results in impaired response to
nucleic acid-stimulated tumor immunity.
The authors were able to show that
TIM-3 up-regulation occurred selectively
in tumor-associated DC (TADC) both in
mouse models of transplantable tumors
and in tumor samples from patients.
Dendritic cells are professional antigen-
presenting cells that orchestrate both
immune tolerance and immune responses.
Through the expression of pattern recog-
nition receptors (PRRs), such as Toll-like
receptors (TLRs) and RAGE, which rec-
ognize pathogen-associated and damage-
associated molecular patterns (PAMPs and
DAMPs, respectively) released by stressed
cells, DCs play an essential role in ini-
tiating innate immune responses against
pathogens and tumors. In particular, a
number of reports demonstrated that
when infiltrating within tumor microen-
vironment, dendritic cells can contrast
tumor progression (Mattei et al., 2009,
2012; Pinto et al., 2012).
The in vivo experiments done by Chiba
and coworkers show that the therapeu-
tic efficacy of nucleic acid treatment is
enhanced when either expression of TIM-
3 is suppressed or when DC are depleted.
Indeed, injections of antibody to TIM-3
significantly suppress melanoma progres-
sion in mice exposed to plasmid DNA
or CpG-ODN adjuvants. Furthermore,
by using a CD11c-DTR tumor mouse
model, where administration of diptheria
toxin suppresses dendritic cell lineage, the
authors show that selective depletion of
DC results in suppression of melanoma
growth following treatment with plas-
mid DNA alone. These data strongly
suggest that DC-expressed TIM-3 con-
trols tumor expansion by interfering with
the pathways involving Toll-like receptors
capable to recognize nucleic acids, such
as TLR3, TLR7, and TLR9. Importantly,
Type I Interferons and IL-12 produced
by conventional and plasmacytoid den-
dritic cells infiltrating the tumor microen-
vironment represent a down-stream signal
that elicits these DNA/TIM-3-dependent
antitumor responses. This assumption is
also strengthtened by a large number
of reports demonstrating that double-
stranded DNA promote the production
of Type I Interferons. Indeed, this occurs
either in vitro, where it was demon-
strated that different DC subsets produce
this cytokine in response to Poly(I:C),
and in vivo by intravenous injection of
Poly(I:C) in mice (Mattei et al., 2010).
Collectively, these observations reveal that
Type I Interferons play a significant role
in such DNA/TIM-3-controlled antitumor
responses.
In their study, Chiba and coworkers
also demonstrate the role of the dan-
ger/stress signal protein HMGB1 in such
TIM-3 dependent pathways. HMGB1 acts
not only as transcriptional factor in the
nucleus but can be released in the extra-
cellular milieu with effects on inflamma-
tion, DC activation and immune responses
by binding nucleic acids. The specific
receptor for HMGB1 so far recognized is
RAGE (Kokkola et al., 2005; Nogueira-
Machado et al., 2011). When expressed
on dendritic cell surface, this receptor
can bind HMGB1, and the function of
this RAGE/HMGB1 complex is to allow
nucleic acids to activate endosome-driven,
TLR-mediated pathways. In their paper,
Chiba and coworkers showed that HMGB1
specifically binds to TIM-3 on dendritic
cell surface and that this HMGB1/TIM-3
complex is then internalized into endo-
somal vesicles. This protein complex
impedes HMGB-1-mediated recruitment
of nucleic acids within the endosomes,
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leading to a decrease of the efficacy
of immune responses to nucleic acids.
Indeed, TIM-3 competes with nucleic
acids to bind the A box of HMGB1,
impeding the HMGB1/DNA association,
and thus blocking the activation of innate
immune system. Therefore, in the sce-
nario where TIM-3 sequester HMGB1
to nucleic acids, the innate immune
responses toward the tumor are blocked
resulting in increased tumor expansion.
The authors further extend the impli-
cations of their findings in cancer
chemotherapy. First, they demonstrate
that TIM-3-expressing DC loaded with
dying tumor cells promote an immuno-
genic response (demonstrated by the
production of Type I Interferons and
IL-12) only when DC were previously
treated with a blocking TIM-3 anti-
body and nucleic acids. In CD11c-DTR
tumor-bearing mice, the authors elegantly
demonstrate that TIM-3 blockade cou-
pled to administration of cisplatin, an
apoptosis-inducing drug (Pruefer et al.,
2008), strongly repress melanoma pro-
gression, and that TIM-3-expressing DC
play a fundamental functional role in this
scenario.
The results produced by Chiba and
coworkers have important implications in
the field of anticancer therapies, as they
demonstrated for the first time that TIM-3
functions as an important negative regu-
lator of innate immune responses within
the tumor microenvironment. Given the
abundant presence of nucleic acids at
the tumor site, released by tumor cells
dying by constitutive or chemotherapy-
induced apoptosis, TIM-3 can be viewed
as a new promising target for anticancer
therapeutic settings to improve vaccina-
tion protocols involving nucleic acids. In
addition, these data will provide new
insight toward an effective and specific
activation of the immunological mem-
ory, and potentially opens new perspec-
tives in the field of chemotherapy. To
this regard, it will be very interesting
to expand and confirm these observa-
tions on TIM-3/HMGB1 by employing
other chemotherapeutic agents, in order
to expect similar effects on suppression
of various other solid tumors, in particu-
lar those that are surgically not reachable,
such as human brain tumors.
Lastly, since TIM-3 exposure on DC
surface is a result of tumor-released
immunosuppressive factors, which occurs
at late stage of tumor development, the
data from Chiba and coworkers provide a
novel mechanism of tumor escape.
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